Dimensional Fund Advisors
CLDX icon

Dimensional Fund Advisors’s Celldex Therapeutics CLDX Stock Holding History

Dimensional Fund Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.6M Buy
1,059,534
+407,818
+63% +$11.1M 0.01% 1711
2025
Q4 		$17.7M Buy
651,716
+394,633
+154% +$10.4M ﹤0.01% 2032
2025
Q3 		$6.65M Buy
257,083
+113,197
+79% +$2.62M ﹤0.01% 2449
2025
Q2 		$2.93M Buy
+143,886
New +$2.8M ﹤0.01% 2659
2024
Q2 		– Sell
-43,431
Closed -$1.82M – 3382
2024
Q1 		$1.82M Sell
43,431
-187,040
-81% -$7.68M ﹤0.01% 2816
2023
Q4 		$9.14M Sell
230,471
-110,879
-32% -$3.26M ﹤0.01% 2357
2023
Q3 		$9.39M Sell
341,350
-112,284
-25% -$3.52M ﹤0.01% 2289
2023
Q2 		$15.4M Sell
453,634
-45,120
-9% -$1.52M ﹤0.01% 2056
2023
Q1 		$17.9M Sell
498,754
-2,322
-0.5% -$100K 0.01% 1963
2022
Q4 		$22.3K Sell
501,076
-33,439
-6% -$1.19M 0.01% 1819
2022
Q3 		$15M Sell
534,515
-77,357
-13% -$2.37M 0.01% 1970
2022
Q2 		$16.5M Buy
611,872
+19,514
+3% +$567K 0.01% 1974
2022
Q1 		$20.2M Buy
592,358
+142,761
+32% +$4.56M 0.01% 1960
2021
Q4 		$17.4M Buy
449,597
+90,963
+25% +$3.96M 0.01% 2062
2021
Q3 		$19.4M Sell
358,634
-790
-0.2% -$37.1K 0.01% 2016
2021
Q2 		$12M Buy
359,424
+56,072
+18% +$1.54M ﹤0.01% 2276
2021
Q1 		$6.25M Sell
303,352
-4,563
-1% -$105K ﹤0.01% 2499
2020
Q4 		$5.39M Sell
307,915
-278
-0.1% -$5K ﹤0.01% 2502
2020
Q3 		$4.57M Buy
308,193
+1,470
+0.5% +$17.2K ﹤0.01% 2470
2020
Q2 		$3.99M Sell
306,723
-39,193
-11% -$174K ﹤0.01% 2551
2020
Q1 		$574K Buy
345,916
+11,060
+3% +$25K ﹤0.01% 3029
2019
Q4 		$747K Hold
334,856
– – ﹤0.01% 3073
2019
Q3 		$713K Hold
334,856
– – ﹤0.01% 3083
2019
Q2 		$897K Buy
334,856
+71,017
+27% +$241K ﹤0.01% 3076
2019
Q1 		$1.3M Buy
263,839
+25,621
+11% +$135K ﹤0.01% 2981
2018
Q4 		$707K Sell
238,218
-7,341
-3% -$36.1K ﹤0.01% 3089
2018
Q3 		$1.66M Sell
245,559
-39,863
-14% -$279K ﹤0.01% 2966
2018
Q2 		$2.16M Buy
285,422
+7,583
+3% +$101K ﹤0.01% 2870
2018
Q1 		$9.71M Buy
277,839
+118,918
+75% +$4.61M ﹤0.01% 2390
2017
Q4 		$6.77M Buy
158,921
+101,468
+177% +$4.35M ﹤0.01% 2513
2017
Q3 		$2.46M Buy
57,453
+1,974
+4% +$74K ﹤0.01% 2807
2017
Q2 		$2.06M Buy
55,479
+22,643
+69% +$1M ﹤0.01% 2842
2017
Q1 		$1.78M Buy
32,836
+26,598
+426% +$1.39M ﹤0.01% 2863
2016
Q4 		$331K Buy
6,238
+695
+13% +$39.5K ﹤0.01% 3147
2016
Q3 		$336K Buy
5,543
+4,103
+285% +$256K ﹤0.01% 3124
2016
Q2 		$95K Buy
1,440
+386
+37% +$24.5K ﹤0.01% 3238
2016
Q1 		$60K Buy
+1,054
New +$119K ﹤0.01% 3254
2015
Q1 		– Sell
-40
Closed -$11K – 3343
2014
Q4 		$11K Sell
40
-10,986
-100% -$2.73M ﹤0.01% 3450
2014
Q3 		$2.14M Sell
11,026
-39,336
-78% -$8.57M ﹤0.01% 2820
2014
Q2 		$12.3M Sell
50,362
-13,290
-21% -$3M 0.01% 2079
2014
Q1 		$16.9M Sell
63,652
-12,032
-16% -$4.61M 0.01% 1742
2013
Q4 		$27.5M Sell
75,684
-143
-0.2% -$55.1K 0.02% 1169
2013
Q3 		$40.3M Sell
75,827
-2,002
-3% -$686K 0.03% 689
2013
Q2 		$18.2M Buy
+77,829
New +$15.3M 0.02% 1388

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Dimensional Fund Advisors's CLDX Position: Q1 2026 in Review

Dimensional Fund Advisors increased its Celldex Therapeutics (CLDX) stake by 63% in Q1 2026, buying an estimated $11.1M and bringing the position to 1,059,534 shares worth $33.6M. The position accounts for 0.01% of the portfolio, ranked #1711.

Dimensional Fund Advisors first reported a position in CLDX in Q2 2013 and has held it in 44 quarters since. The position peaked at $40.3M in Q3 2013. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Dimensional Fund Advisors held 1,059,534 shares of Celldex Therapeutics worth $33.6M as of Q1 2026.
  • Dimensional Fund Advisors bought 407,818 Celldex Therapeutics shares in Q1 2026, an estimated $11.1M.
  • Celldex Therapeutics made up 0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #1711 holding.
  • Dimensional Fund Advisors first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 44 quarters since.
  • Dimensional Fund Advisors's Celldex Therapeutics position peaked at $40.3M in Q3 2013.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.